Mylatabi (Eltrombopag)

Eltrombopag is used to treat hematologic disorders characterized by low platelet counts.

• Immune thrombocytopenia (ITP): Increases platelet counts to reduce bleeding risk in patients with chronic ITP.
• Hepatitis C‑associated thrombocytopenia: Improves platelet production in patients with thrombocytopenia secondary to chronic hepatitis C infection.
• Severe aplastic anemia: Enhances platelet generation as part of therapy for patients with severe aplastic anemia.

• Eltrombopag binds to the transmembrane domain of the thrombopoietin (TPO) receptor (c‑Mpl) on megakaryocyte progenitor cells, mimicking endogenous TPO. This activation triggers intracellular signaling pathways, notably JAK/STAT and MAPK, leading to proliferation and differentiation of megakaryocytes and increased platelet production. The drug’s oral bioavailability allows systemic exposure sufficient to sustain platelet counts in affected patients and contributes to improved hemostasis.

Eltrombopag may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal discomfort.
• Diarrhea: loose stools that may be self‑limiting.
• Fatigue: generalized tiredness.
• Elevated liver enzymes: transient increases in ALT/AST.
• Headache: mild cranial pain.

Serious or Rare Side Effects

• Hepatotoxicity: significant liver injury requiring monitoring.
• Thromboembolic events: arterial or venous clot formation.
• Severe skin reactions: such as Stevens‑Johnson syndrome.
• Bone marrow fibrosis: rare progression of marrow scarring.
• Myelosuppression: unexpected drop in other blood cell lines.

When prescribing Eltrombopag, clinicians should consider several precautionary measures to ensure safe use.

• Baseline liver function: assess ALT/AST before initiating therapy.
• Monitor platelet counts: adjust dose based on weekly platelet monitoring.
• Concomitant anticoagulants: evaluate bleeding risk when used with anticoagulant drugs.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks.
• Drug interactions: review patient’s medication list for known major interactions.
• Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Eltrombopag can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce drug exposure.
• Antacids containing polyvalent cations: decrease oral absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Immunosuppressants (e.g., cyclosporine, tacrolimus): may increase plasma levels.
• Warfarin: potential alteration of INR, requiring closer monitoring.
• Oral contraceptives: possible reduced effectiveness, advise alternative contraception.